Laboratory Data: Know Your Practice. Know Your Patients.

Message from Paradigm’s President, Catherine Veal What a whirlwind this Spring has been for us all! At Paradigm, we’ve stayed very busy throughout the COVID-19 public health emergency and we’re looking forward to helping our clients as they continue telemedicine visits and return to in-person encounters with their patients. Our Benchmark® Presumptive LC-MS/MS testing [...]

By |2020-06-09T14:30:46+00:00June 8th, 2020|Laboratory Data, Newsletter|0 Comments

COVID, Telemedicine and Drug Testing

We know many of you are finding your way through the COVID-19 Public Health Emergency (COVID-19 PHE) and shifting from traditional in-person healthcare practice settings to telemedicine encounters with your patients. We understand that telemedicine presents a significant challenge on many levels, especially when controlled medication is part of the treatment plan. For these [...]

By |2020-06-09T14:20:07+00:00April 5th, 2020|COVID-19 and DEA, Newsletter|0 Comments

DEA and State Positions – Controlled Drugs During the Era of the COVID-19 PHE

Understanding DEA and State Positions on Prescribing Controlled Medication During the COVID-19 Public Health Emergency Paradigm Labs is doing its part to support healthcare providers and their patients during the COVID-19 Public Health Emergency (COVID-19 PHE). To this end, Paradigm Labs has developed a drug testing platform that allows providers and patients to engage [...]

By |2020-06-09T14:50:26+00:00March 30th, 2020|COVID-19 and DEA, Newsletter, Regulatory|0 Comments